IGM Biosciences Stock: Bad News With No Turnaround In Sight
IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell ...
FierceBiotech4h
IGM, Y-mAbs, Passage Bio and more telegraph staff cuts amid restructuring spree
Just two weeks into 2025, January is proving why it’s earned a reputation as the worst month for layoffs. | Just two weeks ...
BioSpace7h
IGM Biosciences Lays Off 73% of Staff, Shrinks Pipeline
Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...
IGM Bio plunges as Wall Street downgrades on portfolio shakeup
IGM Biosciences (IGMS) stock faces sharp selloff as the company abandons two therapeutic candidates, triggering Wall Street ...
GlobalData on MSN10h
IMG Biosciences enacts massive lay-offs after Phase I trial failure
Following the negative Phase I trial outcome for its autoimmune disease treatment, the company is cutting 73% of jobs.
IGM Biosciences price target lowered to $2 from $12 at Truist
Truist analyst Asthika Goonewardene lowered the firm’s price target on IGM Biosciences (IGMS) to $2 from $12 and keeps a Hold rating on the ...
The Armenian Reporter4h
Jefferies Financial Group Reiterates “Hold” Rating for IGM Biosciences (NASDAQ:IGMS)
IGM Biosciences (NASDAQ:IGMS – Get Free Report)‘s stock had its “hold” rating reiterated by Jefferies Financial Group in a ...
Lupus Foundation of America10h
IGM Biosciences Halts Development of Two Investigational Treatments for People with Autoimmune and Inflammatory Diseases
IGM Biosciences announced the discontinuation of imvotamab and IGM-2644 for autoimmune and inflammatory diseases, including ...
IGM Biosciences downgraded to Hold from Buy at Jefferies
Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company discontinued all ...